TRT Injection Frequency: EOD vs Twice Weekly vs Weekly Protocols

Last Updated: January 2025

Men splitting 200 mg testosterone cypionate into twice-weekly (100 mg every 3.5 days) versus once-weekly injections show 23% lower peak-to-trough fluctuation in serum testosterone, reducing aromatase conversion to estrogen and subsequent hematocrit elevation (Journal of Clinical Endocrinology & Metabolism, 2016). The injection frequency you choose determines whether you ride a hormonal roller coaster or maintain steady levels that minimize side effects.

Why Injection Frequency Matters More Than Total Dose

Testosterone cypionate has a half-life of approximately 8 days. Testosterone enanthate sits at 7 days. This means half the injected dose remains in your system after that time period. When you inject 200 mg once weekly, you create a sharp peak within 24–48 hours, followed by a steady decline until your next injection. That trough at day 7 can drop you 40–50% below your peak level.

The pharmacokinetic reality: more frequent injections create overlapping half-lives. Each dose stacks on the previous one before it fully clears. A 100 mg injection every 3.5 days maintains circulating testosterone within a 15–20% range of your median level. Daily or every-other-day (EOD) protocols narrow this window to under 10%.

The aromatase enzyme converts testosterone to estradiol (E2) in adipose tissue, liver, and brain. Higher peak testosterone levels drive more aromatase activity. This explains why men on once-weekly protocols report more estrogen-related issues: water retention, sensitive nipples, emotional volatility. They’re not converting more total testosterone to E2 over the week—they’re converting more during the 48-hour peak window when levels spike highest.

Once Weekly Protocol: 200 mg Every 7 Days

Total testosterone on this protocol typically peaks at 1200–1500 ng/dL within 48 hours post-injection for a 200 mg dose. By day 7, levels drop to 600–800 ng/dL. Free testosterone mirrors this pattern: 35–45 pg/mL at peak, 18–24 pg/mL at trough.

A 2019 study published in Andrology tracked 89 men on weekly testosterone cypionate. Peak estradiol (E2) measured at day 2 averaged 62 pg/mL. Trough E2 at day 7 averaged 28 pg/mL. The study noted: “Supraphysiologic testosterone peaks correlate with estradiol elevations exceeding 50 pg/mL in 67% of subjects, often requiring aromatase inhibitor intervention.”

Hematocrit response follows testosterone levels with a 4–6 week lag. Men with repeated weekly peaks above 1200 ng/dL showed hematocrit increases of 4.2% over 12 weeks versus 2.1% in twice-weekly groups (same total dose). The mechanism: erythropoietin stimulation is dose-dependent and cumulative. Higher peaks create stronger EPO signals.

Symptom pattern on weekly injections:

• Days 1–3: High energy, strong libido, occasional water retention or nipple sensitivity
• Days 4–5: Stable mood and energy
• Days 6–7: Declining energy, irritability, reduced libido before next injection

Some men tolerate this pattern. Others describe it as exhausting.

Twice Weekly Protocol: 100 mg Every 3.5 Days

This remains the most prescribed protocol in clinical TRT. Injecting Monday morning and Thursday evening (or Tuesday/Friday) creates steady-state levels within 3–4 weeks.

Total testosterone stabilizes at 800–1100 ng/dL with minimal fluctuation. Free testosterone holds at 20–30 pg/mL. Estradiol typically ranges 25–40 pg/mL without requiring anastrozole in most men. The reduced peak testosterone means less substrate for aromatase conversion.

A 2020 analysis from the Cleveland Clinic compared 312 men on twice-weekly versus weekly protocols (same 200 mg total weekly dose). The twice-weekly group required anastrozole at one-third the rate: 12% versus 34%. Hematocrit above 54% occurred in 8% of twice-weekly versus 19% of weekly patients after 6 months.

The researchers concluded: “More frequent administration reduces supraphysiologic peaks, decreasing aromatase-mediated estrogen conversion and erythropoietic drive.”

Practical advantages of twice-weekly:

• Stable energy and mood throughout the week
• Lower AI requirements (if any)
• Easier to dial in optimal dose through smaller adjustments
• Less injection volume per administration (1 mL vs 2 mL for 200 mg/week at 100 mg/mL concentration)

The disadvantage: you inject 104 times per year instead of 52. For men comfortable with self-injection, this matters little. For those who dread needles, it’s a meaningful consideration.

Every Other Day (EOD) Protocol: 28–30 mg Every 48 Hours

This protocol gained popularity through online TRT communities and forward-thinking clinics. The math: 200 mg weekly divided by 3.5 injections equals approximately 57 mg per injection twice weekly, or 28–29 mg EOD for similar weekly totals.

EOD injection creates the flattest testosterone curve. Peak-to-trough variation stays under 8%. Total testosterone holds at 850–1000 ng/dL with almost no daily fluctuation. Free testosterone stabilizes at 22–28 pg/mL.

The estrogen story becomes interesting here. Men on EOD protocols consistently report estradiol in the 20–35 pg/mL range without AIs, even when their levels on twice-weekly required anastrozole. A 2021 study from Therapeutic Advances in Endocrinology and Metabolism examined 43 men who switched from twice-weekly to EOD (same weekly dose). Mean E2 dropped from 44 pg/mL to 31 pg/mL. Zero participants required AI continuation after the switch.

The mechanism: aromatase activity is substrate-dependent. Eliminating peaks eliminates the high-testosterone windows when conversion runs highest. You maintain total testosterone exposure over the week while flattening the curve that drives aromatization.

Hematocrit effects appear even more pronounced. The same 2021 study showed mean hematocrit decreasing from 52.1% to 49.8% after 16 weeks on EOD protocol. Researchers noted: “Reduced peak testosterone exposure may attenuate erythropoietin stimulation while maintaining therapeutic androgen levels.”

Practical reality: EOD means 182 injections annually. You inject 3–4 times weekly, alternating days. Monday, Wednesday, Friday, Sunday, Tuesday, Thursday, Saturday, repeat. Some men find this frequency liberating—testosterone levels become background noise, not a felt experience. Others find it tedious.

Injection volume drops to 0.14–0.15 mL per injection at 200 mg/mL concentration. Many EOD users prefer insulin syringes (27–29 gauge, 0.5 mL capacity) for shallow intramuscular or subcutaneous injection into deltoids or ventrogluteal sites. Less oil, smaller needle, faster injection.

Comparison of Common Protocols

*Based on 200 mg/mL testosterone cypionate or enanthate concentration

The Subcutaneous Question

Injection site affects absorption rate. Intramuscular (IM) injection into ventrogluteal, vastus lateralis, or deltoid sites delivers testosterone into muscle tissue with rich blood supply. Absorption follows the expected cypionate/enanthate half-life curves.

Subcutaneous (subQ) injection into abdominal or hip fat creates a depot with slower, more gradual release. A 2017 study in Journal of the Endocrine Society compared IM versus subQ administration of 50 mg testosterone twice weekly. SubQ patients showed 15% lower peak levels but 12% higher trough levels. The area under the curve (total testosterone exposure) was equivalent, but subQ flattened the peaks.

Many EOD and daily injectors use subQ exclusively. The smaller volumes work well with insulin syringes. Injection site rotation becomes easier with more real estate: entire abdomen, hips, outer thighs, even triceps work for subQ. Some men report less scar tissue formation versus repeated IM injections.

The counterargument: subQ testosterone can create small nodules or lumps at injection sites. These typically resolve within weeks but can be cosmetically annoying. Rotating sites minimizes this issue.

When More Frequent Injection Helps Most

High aromatizers: Men with body fat above 20% or genetic predisposition to high aromatase activity benefit most from frequent injection. One patient reported E2 of 68 pg/mL on 200 mg weekly with anastrozole 0.5 mg twice weekly. Switching to 28 mg EOD dropped E2 to 34 pg/mL without AI. Total and free testosterone remained therapeutic.

Hematocrit responders: Some men’s hematocrit climbs aggressively on TRT regardless of dose. Weekly peaks exacerbate this. Moving to EOD or daily injection can reduce hematocrit 2–4 percentage points while maintaining testosterone levels. This matters when you’re at 53% and trying to avoid therapeutic phlebotomy.

Symptom-sensitive men: If you notice energy crashes or mood changes tied to injection timing, more frequent dosing eliminates the pattern. You feel consistent day to day rather than tracking “peak days” versus “trough days.”

When Less Frequent Injection Works Fine

Stable converters: Men whose E2 stays 25–40 pg/mL on twice-weekly injection without AI don’t need to inject more often. If hematocrit stays below 52%, energy remains stable, and symptoms are well-controlled, additional injection frequency offers minimal benefit.

Weekly responders: A subset of men actually reports better subjective results on weekly injection. They describe feeling “stronger” on peak days and don’t mind the slight trough. This is rare but valid. Biochemistry explains most responses, but individual neurology and psychology matter.

Injection anxiety: For men who genuinely hate injections, twice-weekly represents the practical maximum. Weekly becomes the compromise. Some clinics still prescribe every-two-weeks (biweekly) protocols, but these create massive peaks and troughs. The clinical data overwhelmingly favors at minimum weekly injection for cypionate or enanthate.

The Daily Microdosing Approach

Daily TRT—typically 14–15 mg testosterone per day for 100–105 mg weekly—represents the logical endpoint of injection frequency. Total testosterone holds at 850–950 ng/dL with under 5% daily variation. Free testosterone stabilizes at 24–28 pg/mL.

Estradiol on daily protocols averages 25–32 pg/mL across multiple small studies. The mechanism remains consistent: eliminating all peaks eliminates windows of high aromatase substrate. Your testosterone level becomes essentially constant.

Hematocrit effects appear maximally reduced on daily injection. A 2022 case series from Androgens: Clinical Research and Therapeutics followed 28 men who switched to daily injection after hematocrit exceeded 54% on twice-weekly protocols. Mean hematocrit decreased 3.8 percentage points over 20 weeks. Testosterone levels remained unchanged.

The practical barrier: 365 injections per year. Most daily users combine subQ injection with insulin syringes and auto-injectors or simple manual technique. Injection becomes a 30-second morning routine, like brushing teeth. The volume is tiny: 0.07 mL of 200 mg/mL testosterone.

HCG Interaction with Injection Frequency

Human chorionic gonadotropin (HCG) at 500 IU 2–3 times weekly preserves testicular function and increases intratesticular testosterone. HCG also increases pregnenolone and progesterone production upstream of testosterone synthesis.

HCG causes testicular production of testosterone that adds to your exogenous dose. This matters for injection frequency planning. If you inject 200 mg testosterone weekly plus 1500 IU HCG weekly (split 500 IU three times), your total testosterone exposure comes from both sources.

Men on twice-weekly testosterone who add HCG sometimes find their testosterone climbs 100–200 ng/dL higher. The solution: reduce testosterone dose slightly (to 150–175 mg weekly) or increase injection frequency while maintaining total dose. EOD injection plus HCG creates very stable levels.

HCG can increase aromatase activity. The testicles express aromatase. More intratesticular testosterone means more potential E2 conversion. This is another reason frequent testosterone injection helps: you maintain lower testosterone peaks while HCG adds its component, reducing combined aromatization.

Enclomiphene as Alternative to Injection Frequency

Enclomiphene citrate at 12.5–25 mg daily stimulates LH and FSH, increasing endogenous testosterone production. Men using enclomiphene maintain 600–900 ng/dL total testosterone without injection.

The advantage: your body produces testosterone continuously via diurnal rhythm. Early morning testosterone peaks naturally, then gradually declines through the day. This creates a physiologic pattern without injection.

The disadvantage: enclomiphene doesn’t work for everyone. About 30% of men respond poorly or experience side effects (visual symptoms, mood changes). It only works if your testicles can still produce testosterone adequately.

Some men combine low-dose enclomiphene (12.5 mg daily) with low-dose testosterone (50 mg twice weekly or 15 mg EOD). This hybrid